Machine Learning Scientist (Causality)

Synlico Inc. is a resident company of Johnson & Johnson Innovation – JLABS, a premier life science incubator program. Synlico envisions rewriting medicine by bringing causality to cellular biology. We are an AI-powered Drug Discovery startup developing cutting-edge engineered T cell therapies to combat solid tumors with the latest advancements in single-cell bioinformatics, machine learning, and causal discovery. We are a passionate team of young scientists and professionals who value innovation and teamwork. Our research is highly interdisciplinary and team oriented. We are seeking a talented and enthusiastic machine learning scientist who will lead/participate in several of our projects with our science team. Our HQ is at South San Francisco, CA, United States. For more information, please visit www.synlico.com.

Job Description:

This is a remote working position in Canada. As a member of our science team, the machine learning scientist will

    • Design state-of-the-art causal & ML & DL algorithms for biological systems at the cellular level.
    • Foster strong collaboration with bioinformatics, ML, and causal teams and provide expert opinions to project peers.
    • Keep abreast of emerging trends in causal discovery and ML, leading innovation initiatives and incorporating fresh ideas and technologies.

Job Requirement:

    • Ph.D in Computer Science or related technical discipline, or will be graduating with Ph.D before June 2024.
    • Demonstrate a robust research history and strong publication record.
    • Strong foundation in machine learning & deep learning, along with proficiency in related tools such as Pandas, Pytorch, TensorFlow, and Sklearn.
    • Expertise in causal structure discovery & causal inference.
    • Solid coding and problem-solving skills, experience with real word data.
    • Excellent communication and collaboration skills, with the ability to work collaboratively and independently with minimal supervision.
    • Passionate about addressing complex, real-world challenges and creating impactful, innovative solutions.

Interested candidates please submit your CV with a full list of your publications to career@synlico.com 

Synlico is an equal opportunity employer. At Synlico, we value differences and are committed to a diverse workplace that fosters inclusion for all employees. Synlico provides a work environment that respects each individual and is free of all forms of employment discrimination because of race, color, religion, sex, national origin, sexual orientation, gender identity, disability, or veteran status.

Synlico to Present at the BIO Investor Forum

South San Francisco, California, September 26, 2023 – Synlico Inc., an AI-based drug design company focusing on developing potent T-cell therapies against solid tumors, is thrilled to announce its participation in the upcoming 2023 BIO Investor Forum in San Francisco.

In the event, Synlico Inc. will present the development of its computational technology platform, which harnesses state-of-the-art advancements in single-cell bioinformatics, machine learning, and causal discovery.  The platform enables a granular description of the heterogeneity of the tumor microenvironment (TME) and reclassifies patients by their shared TME signatures. The platform can design potent T cell therapies by identifying the causal relationship and causal effects between intracellular elements of T cells and their behaviors in patients’ TME, surmounting the challenges presented by the complex nature of solid tumors and their microenvironments.

Synlico Inc. is a resident company of Johnson & Johnson Innovation – JLABS, a premier life science incubator program. JLABS is a global network of open innovation ecosystems, enabling and empowering innovators to create and accelerate the delivery of life-enhancing health and wellness solutions to patients around the world. As a leader in innovation, JLABS helps pharmaceutical and medical technology entrepreneurs bring healthcare solutions to patients and consumers.

“We are excited to share our science and vision at the Bio Investor Forum. Understanding the heterogeneity of the tumor microenvironment is critical to the efficacy of engineered T-cell therapy. Our platform is designed to identify shared patterns among patients, and understand how these TME patterns exert different impacts on T cells.” Jingwei Lu, CEO of Synlico Inc., said. “We also build a causal mapping between interventions of gene regulation of T cells and their behaviors in patients’ TME, which will enable us to find out the optimal design of potent T cell therapies.”

Synlico’s presentation schedule:

    • Date: October 17, 2023
    • Time: 4:00 pm
    • Venue: Room Franciscan C
                  Hilton San Francisco Union Square, 333 O’Farrell Street, San Francisco, CA 94102

For more information, please visit Bio International event website or Synlico’s website.

 

About Synlico Inc.

Synlico Inc. envisions rewriting medicine by bringing causality to cellular biology. As an AI-powered drug discovery biotech company, Synlico’s primary mission is to develop cutting-edge engineered T cell therapies to combat solid tumors. Harnessing advancements in single-cell bioinformatics, machine learning, and causal discovery, the Synlico team is developing a computational platform that provides a granular description of the heterogeneity of the tumor microenvironment (TME) and reclassifies patients by their unique TME signatures. The Synlico platform will be able to design potent T cell therapies by discovering the causal relationship between intracellular elements of T cells and their behaviors in patients’ TME, surmounting the challenges presented by the complex nature of solid tumors and their microenvironments. Visit www.synlico.com to find out more.

 

Synlico Inc. contacts:

Linda Guo

info@synlico.com